Racura Oncology has started a research collaboration with Purdue University in the US to study how (E,E)-bisantrene (RCDS1) ...
Pancreatic cancer is one of the deadliest cancers worldwide, with a five-year survival rate of 13%. The poor prognosis is due in part both to late detection and the cancer’s capacity to adapt and ...
The Phase 1 monotherapy dose escalation portion of MYCHELANGELO I was designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OTX-2002 ...
• First MYC condensate-modulating small molecule advanced to Development Candidate • Demonstrates potent, selective inhibition of MYC-driven transcription via condensate modulation • Preclinical data ...
Scientists have learned that prostate cancers can vary significantly among patients and that there are often differences within each patient's tumor. However, the study published Aug. 28 in Nature ...
Scientists have learned that prostate cancers can vary significantly among patients and that there are often differences within each patient's tumor. However, the study published Aug. 28 in Nature ...
Targeting a non-encoding stretch of RNA may help shrink tumors caused by an aggressive type of brain cancer in children, according to new research in mice reported March 8 in Cell Reports by Johns ...
Newfindingbuildsuponpreviousconfirmationofmisetionamide’sdirectinhibition of NFkB Directtargetingofthesetwotranscriptionfactorsinhibitsmultipledownstream signaling ...
A new research paper titled "Inhibitory effect of miR-377 on the proliferative and invasive behaviors of prostate cancer cells through the modulation of MYC mRNA via its interaction with BCL-2/Bax, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results